Florida International University has selected Validcare through a sole source agreement to provide its Platform as a Service (PaaS) for hybrid and decentralized clinical trials. This partnership addresses challenges traditional and pandemic-related obstacles present in conducting clinical research.
The selection reflects Validcare’s distinctive approach combining “proven, 21CFR Part 11 compliant, cloud-based technology with almost 10 years of expertise in patient centered clinical research and value-based care models,” according to the announcement.
FIU Study Platform
Under the agreement, FIU will white-label Validcare’s Study platform as “FIU Study,” making it accessible to researchers across the institution. The platform supports site-based, hybrid, and decentralized trials through iOS and Android applications, plus a secure investigator portal and support services.
Patrick McCarthy, CEO of Validcare, stated: “Together, we can create a re-imagined, inclusive research ecosystem powered by real world data and patient experience to deliver better science and products.”
Expanding Access
The initial study launches this fall, enabling broader geographic participant access beyond the traditional 70-100 mile researcher radius, thereby improving patient diversity and inclusion across the United States.